A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Inclusion Criteria

• •Diagnosis of NSCLC with confirmed squamous or non-squamous tumour histology, without known epidermal growth factor receptor (EGFR) mutation
• •Advanced or metastatic disease (Stage IIIb or IV)
• •Patients to be treated with cisplatin/gemcitabine or cisplatin/pemetrexed: No previous systemic treatment with chemotherapy, targeted therapy or investigational agents (except adjuvant therapy if \> 6 months ago); Patients to be treated with docetaxel: ≥ 1 previous treatment with chemotherapy
• •Measurable disease by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• •ECOG performance score 0-1
• •Life expectancy ≥ 3 months
• •Adequate bone marrow-, renal- and hepatic function
• •LVEF ≥ 55% on cardiac ultrasound